Aniline Derivative Anti-RNA Viral Agent
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral agents targeting viral protease and reverse transcriptase lose effectiveness due to high mutation rates in viruses, and existing treatments for viral diseases like hepatitis C and influenza are problematic in terms of adverse reactions and resistance, necessitating a new antiviral agent with broad applications.
Innovation Solution
Development of compounds that inhibit protein kinases in host cells, specifically those controlling viral protein translation, to effectively target RNA viruses such as hepatitis C and influenza, using a compound with the structure of formula I or its pharmaceutically acceptable salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral agents targeting viral protease and reverse transcriptase are used, then viral replication is inhibited, but virus resistance develops rapidly due to high mutation rates
Solution Approach 1:
The patent uses host cell proteins (kinases, ubiquitin-proteasome system) as intermediaries to inhibit viral replication. Instead of directly targeting viral enzymes, the compound interferes with host cell mechanisms that viruses depend on for protein synthesis and degradation, thereby preventing viral replication without directly confronting the highly mutable viral enzymes.
Solution Approach 2:
The invention replaces the mechanical approach of directly inhibiting viral enzymes with a biochemical approach that modulates host cell signaling pathways. The compound acts as a kinase inhibitor, altering the biochemical environment within the host cell to create conditions unfavorable for viral replication, rather than mechanically blocking viral enzyme activity.
2Reliability
If existing antiviral treatments are used, then viral infection is treated, but adverse reactions and cytotoxicity occur
Solution Approach 1:
The patent introduces host cell regulatory mechanisms as intermediaries between the drug and viral replication. The kinase inhibitor modulates host cell signaling pathways that naturally regulate protein synthesis and degradation, using the cell's own regulatory systems to suppress viral replication while minimizing direct toxic effects on the cell.
Solution Approach 2:
The invention enables the host cell to fight the viral infection using its own physiological mechanisms. By inhibiting specific kinases, the compound activates or enhances the cell's natural antiviral responses, protein quality control systems, and degradation pathways, allowing the cell to self-regulate and eliminate viral proteins without requiring directly cytotoxic agents.
Data Source
AI summary
Viruses, and particularly RNA viruses, have high mutation rates. Hence, antiviral agents that have been developed to date targeting protease or reverse transcriptase of viruses have quickly lost their effectiveness and resistant viruses have emerged. Also, in recent years, viral diseases caused by various new viruses such as SARS, avian influenza, and the hepatitis C have become social menaces. Therefore, the development of a novel antiviral agent that can cope with a virus resistant to an existing drug or a new virus and has a wide range of applications has been demanded. The present invention provides a novel anti-RNA viral agent and a method for use thereof. The present invention further provides an anti-RNA viral agent that is also effective against a new virus or a drug-resistant virus, and a method for use thereof.